OCT 16, 2013 07:00 AM PDT

Prognostic, predictive, and surrogate biomarkers in men with castration resistant metastatic prostate cancer

C.E. CREDITS: CE
Speakers
  • Associate Professor of Medicine and Surgery, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University
    Biography
      Andrew J. Armstrong, MD, ScM, is co-program leader of the genitourinary oncology research program, part of the oncology clinical trials shared resource of the Duke Comprehensive Cancer Center. Armstrong is an internationally recognized expert in prostate cancer outcomes studies in men with castration-resistant metastatic disease, including nomograms and risk group models on prognosis. His research is focused on the development of experimental therapeutics in advanced prostate cancer, particularly those targeting the PI3 kinase/mTOR pathways, as well as the development of prognostic and predictive biomarkers of treatment efficacy, particularly with a focus on circulating tumor cell biology and epithelial-mesenchymal transition (epithelial plasticity). Armstrong is the principal investigator on four investigator-initiated clinical trials and approximately 10 industry or cooperative group sponsored clinical trials, as well as several correlative science studies. In addition to co-directing a clinical research program in genitourinary malignancies, Armstrong serves on the Duke IRB and cancer protocol committee, and is an active member of the Duke Comprehensive Cancer Centers editorial advisory and fellowship committees, and serves as the editor of the Duke Prostate Center newsletter [link]. Armstrongs laboratory collaborates with the laboratory of Mariano Garcia-Blanco, MD, PhD, a renowned RNA biologist, to study alternative RNA splicing as it applies to prostate cancer metastasis and EMT. After completing his fellowship in medical oncology at Johns Hopkins in 2006, Armstrong received his masters of science in clinical investigation from the Johns Hopkins Bloomberg School of Public Health in 2008. Armstrong is a recipient of a Prostate Cancer Foundation Young Investigator Award (2008-2011), an American Society of Clinical Oncology Young Investigator Award (2005-2008), an American Association for Cancer Research Clinical and Translational Fellowship (2005-2008), and has received a Department of Defense Prostate Cancer Research Program Physician Research Training Award (2010-2015). He serves on the National Comprehensive Cancer Center's prostate cancer guidelines panel. Armstrong has published extensively on prostate cancer experimental therapies and prognostic models, including peer reviewed articles, reviews, and numerous book chapters and abstracts.

    Abstract:

    With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess benefit. While prognostic factors describe natural history, predictive biomarkers are factors related to the disease or the host that are associated with improvements in outcomes, such as survival, due to specific therapies. Surrogate biomarkers provide an early estimate of treatment effect as an intermediate endpoint for outcomes such as survival. Such biomarkers have become of increasing importance in oncology to maximize the benefits of novel systemic agents while minimizing the harms to individual patients and the costs to society. Given the number of newly approved and expensive systemic therapies, including novel hormonal therapies, chemotherapies, immunotherapies, and bone microenvironment-targeting therapies, predictive biomarkers are needed to give physicians a more rational sense of matching the right patient to the right therapy sequence at a given time. Here I discuss prognostic and potential predictive biomarkers in men with CRPC and discuss their potential role in the management of men with metastatic disease. Learning objectives: 1. Define prognostic and predictive biomarkers and apply this knowledge to metastatic prostate cancer patients based on established biomarkers in the castration-resistant setting. 2. Understand the role of surrogate biomarkers in drug development, particularly with respect to metastatic prostate cancer.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    Loading Comments...